½ÃÀ庸°í¼­
»óǰÄÚµå
1321412

µ¿Á¤¸Æ·ç(AVF) ±â±â ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : À¯Çüº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2023-2030³â)

Arteriovenous Fistula Devices Market Size, Share & Trends Analysis Report By Type (AVF Creation Devices, AVF Monitoring Devices, AVF Maintenance Devices), By End-use, By Region, And Segment Forecasts, 2023 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 100 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

µ¿Á¤¸Æ·ç(AVF) ±â±â ½ÃÀå ¼ºÀå ¹× µ¿Çâ

Grand View ResearchÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é µ¿Á¤¸Æ·ç(AVF) ±â±â ¼¼°è ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 5¾ï 5,660¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

AVF´Â µ¿¸Æ°ú Á¤¸ÆÀÇ ºñÁ¤»óÀûÀÎ ¿¬°á·Î ¼±ÃµÀû ¿äÀÎ, ¿Ü»ó, ¼ö¼ú·Î ÀÎÇØ ¹ß»ýÇÒ ¼ö ÀÖÀ¸¸ç, 2023³âºÎÅÍ 2030³â±îÁö 7.6%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ·¯ÇÑ ºñÁ¤»óÀûÀÎ ¿¬°áÀº »çÁö¿Í °£°ú ³ú¸¦ Æ÷ÇÔÇÑ ³»ºÎ Àå±â ¸ðµÎ¿¡¼­ ÀÚÁÖ °üÂûµË´Ï´Ù. ÀÇ·á ºÐ¾ß¿¡¼­ AVF´Â Ç÷¾× Åõ¼®ÀÌ ÇÊ¿äÇÑ ¸»±â ½ÅºÎÀüÁõ(ESRD) ȯÀÚ¸¦ À§ÇØ ÀǵµÀûÀ¸·Î ¸¸µé¾îÁö¸ç, AVF¸¦ ¸¸µé¸é ÀÇ·á ¼­ºñ½º Á¦°øÀÚ´Â È¿À²ÀûÀÎ Åõ¼® Ä¡·á¸¦ À§ÇØ Ç÷·ù¿¡ ´ëÇÑ ½Å·ÚÇÒ ¼ö ÀÖ°í ¿µ±¸ÀûÀÎ Á¢±Ù ÁöÁ¡À» ±¸ÃàÇÒ ¼ö ÀÖ½À´Ï´Ù.

AVF ±â±â ½ÃÀåÀº Ç÷¾× Åõ¼®ÀÌ ÇÊ¿äÇÑ ESRDÀÇ À¯º´·ü Áõ°¡¸¦ Æ÷ÇÔÇÑ ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖÀ¸¸ç, AVF´Â Åõ¼® Ä¡·á¸¦ À§ÇÑ ½Å·ÚÇÒ ¼ö ÀÖ´Â Ç÷°ü Á¢±ÙÀ» Á¦°øÇϱâ À§ÇØ ¸¸µé¾îÁý´Ï´Ù. ¶ÇÇÑ, Ç÷°ü ³» Ä¡·á ¹× »öÀü¼ú°ú °°Àº ÃÖ¼Ò Ä§½ÀÀû ½Ã¼úÀÇ ¹ßÀüÀº AVF ±â±â¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

ÁÖ¿ä ¾÷üµéÀº ½ÃÀå Áö¹è·ÂÀ» ³ôÀ̱â À§ÇØ Àμö, ÇÕº´, Á¦ÈÞ, °­·ÂÇÑ R&D Ȱµ¿°ú °°Àº Àü·«Àû ÀÌ´Ï¼ÅÆ¼ºê¸¦ Àû±ØÀûÀ¸·Î ½ÇÇàÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀÌ´Ï¼ÅÆ¼ºê´Â Á¦Ç° Æ÷Æ®Æú¸®¿À¸¦ °­È­Çϰí, ½ÃÀå ÀÔÁö¸¦ È®´ëÇϸç, AVF ±â±â ±â¼ú Çõ½ÅÀ» ÃËÁøÇÏ´Â °ÍÀ» ¸ñÇ¥·Î Çϰí ÀÖ½À´Ï´Ù.

¿¹¸¦ µé¾î, VentureMed GroupÀº 2022³â 5¿ù 'Flex Vessel Prep before PTA for the treatment of obstructive lesions in the native AVF'¶ó´Â ¹«ÀÛÀ§ ´ëÁ¶±º ÀÓ»ó½ÃÇè(RCT) µî·ÏÀ» ¿Ï·áÇß½À´Ï´Ù. µî·ÏÀ» ¿Ï·áÇß½À´Ï´Ù. ÀÌ ÀÓ»ó½ÃÇèÀº »óÁö AVFÀÇ Æó¼â¼º º´º¯À» Ä¡·áÇϱâ À§ÇØ °æÇÇÀû °ü»óµ¿¸ÆÁßÀç¼ú(PTA) Àü¿¡ Flex Vessel Prep ½Ã½ºÅÛÀ» »ç¿ëÇÏ¿© PTA ´Üµ¶ ½Ã¼ú°ú ºñ±³ÇÏ¿© 6°³¿ù ÈÄ ÀÏÂ÷ °³Á¸¼ºÀ» Æò°¡Çϱâ À§ÇØ ¼³°èµÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ ¿¬±¸ ÀÌ´Ï¼ÅÆ¼ºê´Â ÀÓ»óÀû Áõ°Å¸¦ »ý¼ºÇϰí AVF ±â±âÀÇ À¯È¿¼º°ú ¾ÈÀü¼ºÀ» ÀÔÁõÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù.

µû¶ó¼­ ±â¾÷ÀÇ ¿¬±¸°³¹ß¿¡ ´ëÇÑ ÅõÀÚ´Â AVFÀÇ »ýÁ¸À²À» ³ôÀ̰í, ÇÕº´ÁõÀ» ÃÖ¼ÒÈ­Çϸç, AVF ȯÀÚ¿¡°Ô ¿ì¼öÇÑ ¼Ö·ç¼ÇÀ» Á¦°øÇÒ ¼ö ÀÖ´Â Çõ½ÅÀûÀÎ ±â±âÀÇ µµÀÔÀ» ±â´ëÇÒ ¼ö ÀÖ½À´Ï´Ù.

AVF ±â±â ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

  • 2022³â Á¦ÀÛ ºÎ¹®Àº 46.97%ÀÇ °¡Àå Å« ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Á¦ÀÛ ºÎ¹®Àº AVF ½Ã¼úÀ» È¿°úÀûÀÌ°í ¼º°øÀûÀ¸·Î ¼öÇàÇÏ¿© ÃÖÀûÀÇ Åõ¼® Ä¡·á¸¦ °¡´ÉÇÏ°Ô Çϰí ȯÀÚ °á°ú¸¦ °³¼±ÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Çõ½ÅÀûÀÎ Á¦ÀÛ ±â¼ú°ú ±â¼ú ¹ßÀüÀº ¼º°ø·ü Çâ»ó, ÇÕº´Áõ °¨¼Ò, ȯÀÚ Ä¡·á °³¼±À¸·Î À̾îÁ® ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
  • 2022³â¿¡´Â º´¿ø ºÎ¹®ÀÌ 54.20%·Î °¡Àå Å« ¼öÀÍ Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ ¿ìÀ§´Â °í±Þ ÀÎÇÁ¶ó, ¼÷·ÃµÈ ÀÇ·á Àü¹®°¡ÀÇ °¡¿ë¼º, º´¿ø¿¡¼­ AVF ±â±âÀÇ »ç¿ëÀ» ´õ¿í ÃËÁøÇÏ´Â »óȯ ½Ã½ºÅÛ¿¡ ´ëÇÑ Á¢±Ù¼º µîÀÇ ¿äÀο¡ ±âÀÎÇÕ´Ï´Ù.
  • 2022³â¿¡´Â ºÏ¹Ì Áö¿ªÀÌ 47.59%·Î ¾ÐµµÀûÀÎ ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ ³ôÀº ½ÃÀå Á¡À¯À²Àº ÁÖ·Î ÀÌ Áö¿ªÀÇ ESRD À¯º´·ü Áõ°¡¿Í Åõ¼® Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ÀÎÇØ È¿°úÀûÀÎ AVF ±â±â¿¡ ´ëÇÑ ¿ä±¸°¡ Áõ°¡Ç߱⠶§¹®ÀÔ´Ï´Ù.
  • ÁÖ¿ä ½ÃÀå ±â¾÷Àº Medtronic, BD, Teleflex Incorporated, Fresenius Medical Care AG & Co.KGaA, B. Braun SE, Polymedicure, NxStage Medical, Inc, Laminate Medical Technologies µîÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

  • ½ÃÀå ¼¼ºÐÈ­¿Í ¹üÀ§
  • Áö¿ª ¹üÀ§
  • ÃßÁ¤¡¤¿¹Ãø ŸÀÓ¶óÀÎ
  • Á¶»ç ¹æ¹ý
  • Á¤º¸ Á¶´Þ
  • Á¤º¸ ºÐ¼®
  • ½ÃÀå Çü¼º°ú µ¥ÀÌÅÍ ½Ã°¢È­
  • ¸ðµ¨ »ó¼¼
  • 2Â÷ Á¤º¸ ¸®½ºÆ®

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå º¯¼ö, µ¿Çâ ¹× ¹üÀ§

  • ½ÃÀå °èÅë Àü¸Á
    • »óºÎ ½ÃÀå Àü¸Á
    • °ü·Ã/ºÎ¼ö ½ÃÀå Àü¸Á
  • ½ÃÀå µ¿Çâ°ú Àü¸Á
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
  • »ç¾÷ ȯ°æ ºÐ¼®
    • PESTLE ºÐ¼®
    • Porter's Five Forces ºÐ¼®
  • COVID-19 °¨¿°ÁõÀÇ ¿µÇ⠺м®

Á¦4Àå À¯Çü ºñÁö´Ï½º ºÐ¼®

  • AVF ±â±â ½ÃÀå : À¯Çü º¯µ¿ ºÐ¼®, 2022³â ¹× 2030³â
  • Á¦ÀÛ
  • ¸ð´ÏÅ͸µ
  • À¯Áöº¸¼ö

Á¦5Àå ÃÖÁ¾ ¿ëµµ ºñÁö´Ï½º ºÐ¼®

  • AVF ±â±â ½ÃÀå : ÃÖÁ¾ ¿ëµµ º¯µ¿ ºÐ¼®, 2022³â ¹× 2030³â
  • º´¿ø
  • ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ
  • Åõ¼® ¼¾ÅÍ

Á¦6Àå Áö¿ª ºñÁö´Ï½º ºÐ¼®

  • Áö¿ª ½ÃÀå ÇöȲ
  • ºÏ¹Ì
    • ºÏ¹ÌÀÇ AVF ±â±â ½ÃÀå
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • À¯·´ÀÇ AVF ±â±â ½ÃÀå
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • µ§¸¶Å©
    • ½º¿þµ§
    • ³ë¸£¿þÀÌ
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ AVF ±â±â ½ÃÀå
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • Çѱ¹
    • È£ÁÖ
    • ű¹
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ AVF ±â±â ½ÃÀå
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîÆ¼³ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ AVF ±â±â ½ÃÀå
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • Äí¿þÀÌÆ®

Á¦7Àå °æÀï »óȲ

  • ±â¾÷ ºÐ·ù
  • Àü·« ¸ÅÇÎ
    • Ãëµæ
    • Çù¾÷
    • »õ·Î¿î Ç÷§Æû ¹ßÇ¥
    • ±âŸ
  • ±â¾÷ °³¿ä¡¤¸®½ºÆ®
    • BD
    • Medtronic
    • Teleflex Incorporated
    • Fresenius Medical Care AG &Co. KGaA
    • Polymedicure
    • NxStage Medical, Inc
    • Laminate Medical Technologies
    • B. Braun SE
ksm 23.09.06

AV Fistula Devices Market Growth & Trends

The global AV fistula devices market size is expected to reach USD 556.6 million by 2030, according to a new report by Grand View Research, Inc. The market is expected to grow at a CAGR of 7.6% from 2023 to 2030. AVFs are abnormal connections between arteries and veins, which can arise from congenital factors, trauma, or surgical procedures. These abnormal connections are frequently observed in both limbs and internal organs, including the liver and brain. In the context of healthcare, AVFs are deliberately established for patients suffering from End-stage Renal Disease (ESRD) who necessitate hemodialysis. By creating AVFs, healthcare providers can establish a dependable and enduring access point to the bloodstream for efficient dialysis treatments.

The market for arteriovenous fistula (AVF) devices is driven by several factors, including the rising prevalence of ESRD necessitating hemodialysis, where AVFs are created to provide reliable vascular access for dialysis treatments. In addition, advancements in minimally invasive procedures, such as endovascular techniques and embolization, have fueled the demand for AVF devices.

Key players are actively implementing strategic initiatives, including acquisitions, mergers, collaborations, and robust research and development activities, to enhance their market dominance. These initiatives aim to strengthen their product portfolios, expand their market presence, and drive innovation in AVF device technologies.

For instance, in May 2022 VentureMed Group completed the enrollment of a Randomized Controlled Trial (RCT) named 'Flex Vessel Prep before PTA for the treatment of obstructive lesions in the native AVF.' This clinical trial was designed to evaluate the primary patency at six months by utilizing the Flex Vessel Prep system before Percutaneous Transluminal Angioplasty (PTA), compared to PTA alone, for treating obstructive lesions in native AVFs in the upper extremity. Such research initiatives play a crucial role in generating clinical evidence and demonstrating the efficacy and safety of AVF devices.

Thus, as companies invest in research and development, the market can expect the introduction of innovative devices that enhance AVF patency, minimize complications, and provide superior solutions for patients with AVFs.

AV Fistulas Devices Market Report Highlights

  • In 2022, the AVF creation devices segment held the largest revenue share of 46.97%. AVF creation devices play a crucial role in enabling effective and successful AVF procedures, allowing for optimal dialysis treatment and improving patient outcomes. The advancement of innovative AVF creation technologies and techniques further drives the growth of this segment, as they offer improved success rates, reduced complications, and enhanced patient care
  • In 2022, the hospital segment held the largest revenue share of 54.20%. This dominance can be attributed to the factors such as the availability of advanced infrastructure, skilled healthcare professionals, and access to reimbursement systems that further fuel the utilization of AVF devices in hospitals
  • In 2022, North America held the dominant revenue share of 47.59%. This significant market share is primarily attributed to the increasing prevalence of ESRD in the region has led to a higher demand for dialysis treatment, creating a need for effective AVF devices
  • Key market players include Medtronic; BD; Teleflex Incorporated; Fresenius Medical Care AG & Co. KGaA., B. Braun SE; Polymedicure; NxStage Medical, Inc.; and Laminate Medical Technologies

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Market Definitions
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Trends and Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Market Driver Analysis
    • 3.3.2. Market Restraint Analysis
  • 3.4. Business Environment Analysis
    • 3.4.1. PESTLE Analysis
    • 3.4.2. Porter's Five Forces Analysis
  • 3.5. COVID-19 Impact Analysis

Chapter 4. Type Business Analysis

  • 4.1. Arteriovenous Fistulas Device (AVF) Market: Type Movement Analysis, 2022 & 2030
  • 4.2. AVF Creation Devices
    • 4.2.1. AVF Creation Devices Market, 2018 - 2030 (USD Million)
      • 4.2.1.1. Surgical Instruments
      • 4.2.1.1.1. Surgical Instruments Market, 2018 - 2030 (USD Million)
      • 4.2.1.2. Vascular Grafts
      • 4.2.1.2.1. Vascular Grafts Market, 2018 - 2030 (USD Million)
      • 4.2.1.3. Angioplasty Balloons
      • 4.2.1.3.1. Angioplasty Balloons Market, 2018 - 2030 (USD Million)
      • 4.2.1.4. Others
      • 4.2.1.4.1. Others Market, 2018 - 2030 (USD Million)
  • 4.3. AVF Monitoring Devices
    • 4.3.1. AVF Monitoring Devices Market, 2018 - 2030 (USD Million)
      • 4.3.1.1. Doppler Ultrasound
      • 4.3.1.1.1. Doppler Ultrasound Market, 2018 - 2030 (USD Million)
      • 4.3.1.2. Pressure Monitoring Systems
      • 4.3.1.2.1. Pressure Monitoring Systems Market, 2018 - 2030 (USD Million)
      • 4.3.1.3. Others
      • 4.3.1.3.1. Others Market, 2018 - 2030 (USD Million)
  • 4.4. AVF Maintenance Devices
    • 4.4.1. AVF Maintenance Devices Market, 2018 - 2030 (USD Million)
      • 4.4.1.1. Central Venous Catheters
      • 4.4.1.1.1. Central Venous Catheters Market, 2018 - 2030 (USD Million)
      • 4.4.1.2. Stents
      • 4.4.1.2.1. Stents Market, 2018 - 2030 (USD Million)
      • 4.4.1.3. Others
      • 4.4.1.3.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. End-Use Business Analysis

  • 5.1. Arteriovenous Fistulas Device (AVF) Market: End-use Movement Analysis, 2022 & 2030
  • 5.2. Hospitals
    • 5.2.1. Hospitals Market, 2018 - 2030 (USD Million)
  • 5.3. Ambulatory Surgical Centers
    • 5.3.1. Ambulatory Surgical Centers Market, 2018 - 2030 (USD Million)
  • 5.4. Dialysis Centers
    • 5.4.1. Dialysis Centers Market, 2018 - 2030 (USD Million)

Chapter 6. Regional Business Analysis

  • 6.1. Regional Market Snapshot
  • 6.2. North America
    • 6.2.1. North America Arteriovenous Fistulas Device (AVF) Market, 2018 - 2030 (USD Million)
    • 6.2.2. U.S.
      • 6.2.2.1. U.S. Arteriovenous Fistulas Device (AVF) Market, 2018 - 2030 (USD Million)
      • 6.2.2.2. Key Country Dynamics
      • 6.2.2.3. Regulatory Framework
      • 6.2.2.4. Competitive Scenario
    • 6.2.3. Canada
      • 6.2.3.1. Canada Arteriovenous Fistulas Device (AVF) Market, 2018 - 2030 (USD Million)
      • 6.2.3.2. Key Country Dynamics
      • 6.2.3.3. Regulatory Framework
      • 6.2.3.4. Competitive Scenario
  • 6.3. Europe
    • 6.3.1. Europe Arteriovenous Fistulas Device (AVF) Market, 2018 - 2030 (USD Million)
    • 6.3.2. Germany
      • 6.3.2.1. Germany Arteriovenous Fistulas Device (AVF) Market, 2018 - 2030 (USD Million)
      • 6.3.2.2. Key Country Dynamics
      • 6.3.2.3. Regulatory Framework
      • 6.3.2.4. Competitive Scenario
    • 6.3.3. UK
      • 6.3.3.1. UK Arteriovenous Fistulas Device (AVF) Market, 2018 - 2030 (USD Million)
      • 6.3.3.2. Key Country Dynamics
      • 6.3.3.3. Regulatory Framework
      • 6.3.3.4. Competitive Scenario
    • 6.3.4. France
      • 6.3.4.1. France Arteriovenous Fistulas Device (AVF) Market, 2018 - 2030 (USD Million)
      • 6.3.4.2. Key Country Dynamics
      • 6.3.4.3. Regulatory Framework
      • 6.3.4.4. Competitive Scenario
    • 6.3.5. Italy
      • 6.3.5.1. Italy Arteriovenous Fistulas Device (AVF) Market, 2018 - 2030 (USD Million)
      • 6.3.5.2. Key Country Dynamics
      • 6.3.5.3. Regulatory Framework
      • 6.3.5.4. Competitive Scenario
    • 6.3.6. Spain
      • 6.3.6.1. Spain Arteriovenous Fistulas Device (AVF) Market, 2018 - 2030 (USD Million)
      • 6.3.6.2. Key Country Dynamics
      • 6.3.6.3. Regulatory Framework
      • 6.3.6.4. Competitive Scenario
    • 6.3.7. Denmark
      • 6.3.7.1. Denmark Arteriovenous Fistulas Device (AVF) Market, 2018 - 2030 (USD Million)
      • 6.3.7.2. Key Country Dynamics
      • 6.3.7.3. Regulatory Framework
      • 6.3.7.4. Competitive Scenario
    • 6.3.8. Sweden
      • 6.3.8.1. Sweden Arteriovenous Fistulas Device (AVF) Market, 2018 - 2030 (USD Million)
      • 6.3.8.2. Key Country Dynamics
      • 6.3.8.3. Regulatory Framework
      • 6.3.8.4. Competitive Scenario
    • 6.3.9. Norway
      • 6.3.9.1. Norway Arteriovenous Fistulas Device (AVF) Market, 2018 - 2030 (USD Million)
      • 6.3.9.2. Key Country Dynamics
      • 6.3.9.3. Regulatory Framework
      • 6.3.9.4. Competitive Scenario
  • 6.4. Asia Pacific
    • 6.4.1. Asia Pacific Arteriovenous Fistulas Device (AVF) Market, 2018 - 2030 (USD Million)
    • 6.4.2. Japan
      • 6.4.2.1. Japan Arteriovenous Fistulas Device (AVF) Market, 2018 - 2030 (USD Million)
      • 6.4.2.2. Key Country Dynamics
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Competitive Scenario
    • 6.4.3. China
      • 6.4.3.1. China Arteriovenous Fistulas Device (AVF) Market, 2018 - 2030 (USD Million)
      • 6.4.3.2. Key Country Dynamics
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Competitive Scenario
    • 6.4.4. India
      • 6.4.4.1. India Arteriovenous Fistulas Device (AVF) Market, 2018 - 2030 (USD Million)
      • 6.4.4.2. Key Country Dynamics
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Competitive Scenario
    • 6.4.5. South Korea
      • 6.4.5.1. South Korea Arteriovenous Fistulas Device (AVF) Market, 2018 - 2030 (USD Million)
      • 6.4.5.2. Key Country Dynamics
      • 6.4.5.3. Regulatory Framework
      • 6.4.5.4. Competitive Scenario
    • 6.4.6. Australia
      • 6.4.6.1. Australia Arteriovenous Fistulas Device (AVF) Market, 2018 - 2030 (USD Million)
      • 6.4.6.2. Key Country Dynamics
      • 6.4.6.3. Regulatory Framework
      • 6.4.6.4. Competitive Scenario
    • 6.4.7. Thailand
      • 6.4.7.1. Thailand Arteriovenous Fistulas Device (AVF) Market, 2018 - 2030 (USD Million)
      • 6.4.7.2. Key Country Dynamics
      • 6.4.7.3. Regulatory Framework
      • 6.4.7.4. Competitive Scenario
  • 6.5. Latin America
    • 6.5.1. Latin America Arteriovenous Fistulas Device (AVF) Market, 2018 - 2030 (USD Million)
    • 6.5.2. Brazil
      • 6.5.2.1. Brazil Arteriovenous Fistulas Device (AVF) Market, 2018 - 2030 (USD Million)
      • 6.5.2.2. Key Country Dynamics
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Competitive Scenario
    • 6.5.3. Mexico
      • 6.5.3.1. Mexico Arteriovenous Fistulas Device (AVF) Market, 2018 - 2030 (USD Million)
      • 6.5.3.2. Key Country Dynamics
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Competitive Scenario
    • 6.5.4. Argentina
      • 6.5.4.1. Argentina Arteriovenous Fistulas Device (AVF) Market, 2018 - 2030 (USD Million)
      • 6.5.4.2. Key Country Dynamics
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. Competitive Scenario
  • 6.6. MEA
    • 6.6.1. MEA Arteriovenous Fistulas Device (AVF) Market, 2018 - 2030 (USD Million)
    • 6.6.2. South Africa
      • 6.6.2.1. South Africa Arteriovenous Fistulas Device (AVF) Market, 2018 - 2030 (USD Million)
      • 6.6.2.2. Key Country Dynamics
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Competitive Scenario
    • 6.6.3. Saudi Arabia
      • 6.6.3.1. Saudi Arabia Arteriovenous Fistulas Device (AVF) Market, 2018 - 2030 (USD Million)
      • 6.6.3.2. Key Country Dynamics
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Competitive Scenario
    • 6.6.4. UAE
      • 6.6.4.1. UAE Arteriovenous Fistulas Device (AVF) Market, 2018 - 2030 (USD Million)
      • 6.6.4.2. Key Country Dynamics
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Competitive Scenario
    • 6.6.5. Kuwait
      • 6.6.5.1. UAE Arteriovenous Fistulas Device (AVF) Market, 2018 - 2030 (USD Million)
      • 6.6.5.2. Key Country Dynamics
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Competitive Scenario

Chapter 7. Competitive Landscape

  • 7.1. Company Categorization
  • 7.2. Strategy Mapping
    • 7.2.1. Acquisition
    • 7.2.2. Collaborations
    • 7.2.3. New Platform Launches
    • 7.2.4. Others
  • 7.3. Company Profiles/Listing
    • 7.3.1. BD
      • 7.3.1.1. Company Overview
      • 7.3.1.2. Financial Performance
      • 7.3.1.3. Platform Benchmarking
      • 7.3.1.4. Strategic Initiatives
    • 7.3.2. Medtronic
      • 7.3.2.1. Company Overview
      • 7.3.2.2. Financial Performance
      • 7.3.2.3. Platform Benchmarking
      • 7.3.2.4. Strategic Initiatives
    • 7.3.3. Teleflex Incorporated
      • 7.3.3.1. Company Overview
      • 7.3.3.2. Financial Performance
      • 7.3.3.3. Platform Benchmarking
      • 7.3.3.4. Strategic Initiatives
    • 7.3.4. Fresenius Medical Care AG & Co. KGaA
      • 7.3.4.1. Company Overview
      • 7.3.4.2. Financial Performance
      • 7.3.4.3. Platform Benchmarking
      • 7.3.4.4. Strategic Initiatives
    • 7.3.5. Polymedicure
      • 7.3.5.1. Company Overview
      • 7.3.5.2. Financial Performance
      • 7.3.5.3. Platform Benchmarking
      • 7.3.5.4. Strategic Initiatives
    • 7.3.6. NxStage Medical, Inc
      • 7.3.6.1. Company Overview
      • 7.3.6.2. Financial Performance
      • 7.3.6.3. Platform Benchmarking
      • 7.3.6.4. Strategic Initiatives
    • 7.3.7. Laminate Medical Technologies
      • 7.3.7.1. Company Overview
      • 7.3.7.2. Financial Performance
      • 7.3.7.3. Platform Benchmarking
      • 7.3.7.4. Strategic Initiatives
    • 7.3.8. B. Braun SE
      • 7.3.8.1. Company Overview
      • 7.3.8.2. Financial Performance
      • 7.3.8.3. Platform Benchmarking
      • 7.3.8.4. Strategic Initiatives
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦